HLA haploidentical hematopoietic cell transplantation using clofarabine and busulfan for refractory pediatric hematological malignancy.
HLA haploidentical hematopoietic cell transplantation using clofarabine and busulfan for refractory pediatric hematological malignancy.
复制标题
使用氯法拉滨和白消安进行 HLA 单倍相合造血细胞移植治疗难治性儿科血液恶性肿瘤。
DOI：
10.1007/s12185-017-2187-3
复制
发表时间：
2017
期刊：
影响因子：
2.1
通讯作者：
Morio T.
中科院分区：
文献类型：
--
作者：
Takagi M;Ishiwata Y;Aoki Y;Miyamoto S;Hoshino A;Matsumoto K;Nishimura A;Tanaka M;Yanagimachi M;Mitsuiki N;Imai K;Kanegane H;Kajiwara M;Takikawa K;Mae T;Tomita O;Fujimura J;Yasuhara M;Tomizawa D;Mizutani S;Morio T.
本研究对3例难治性儿童白血病患者进行了单倍体造血细胞移植（HCT）调节，采用氯法拉滨和基于血药浓度-时间曲线（AUC）的靶区调节。2例已接受多次移植患者的目标AUC分别为3600 μmol min/L和4000 μmol min/L，唐氏综合征患者的目标AUC为3000 μmol min/L。在所有病例中，方案相关的毒性耐受良好。在整个随访期间（31 - 167周），三名患者均保持细胞学缓解。因此，对于复发性或难治性儿童白血病，单倍体HCT调节联合氯法拉滨和靶向auc的布苏凡调节可能是更好的选择。
Haploidentical hematopoietic cell transplantation (HCT) conditioning with clofarabine and target area under the blood concentration–time curve (AUC)-based busulfan adjustment was performed in three patients with refractory pediatric leukemia. The target AUC for two patients who had already received multiple transplantations was 3600 and 4000 μmol min/L, and that for the patient with Down’s syndrome was 3000 μmol min/L. Regimen-related toxicity was well tolerated in all cases. All three maintained cytological remission throughout the follow-up period (between 31 and 167 weeks). Thus, haploidentical HCT conditioning with clofarabine and target AUC-based busulfan adjustment may be a preferable option for children with recurrent or refractory pediatric leukemia.